期刊
ANNALS OF ONCOLOGY
卷 24, 期 10, 页码 2522-2526出版社
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdt248
关键词
neoadjuvant chemotherapy; molecular characterization; residual disease; resistance; triple receptor-negative breast cancer
类别
资金
- Komen for the Cure Catalystic Award [KG090341]
- American Cancer Society Research Scholar Grant [121329-RSG-11-187-01-TBG]
- National Cancer Institute through The University of Texas MD Anderson's Cancer Center Support Grant [P30 CA016672]
- [K23CA121994-01]
In this study, we used functional proteomics to determine the molecular characteristics of residual triple receptor-negative breast cancer (TNBC) patients after neoadjuvant systemic chemotherapy (NCT) and their relationship with patient outcomes in order to identify potential targets for therapy. Protein was extracted from 54 residual TNBCs, and 76 proteins related to breast cancer signaling were measured by reverse phase protein arrays (RPPAs). Univariable and multivariable Cox proportional hazard models were fitted for each protein. Survival outcomes were estimated by the Kaplan-Meier product limit method. Training and cross validation were carried out. The coefficients estimated from the multivariable Cox model were used to calculate a risk score (RS) for each sample. Multivariable analysis using the top 25 proteins from univariable analysis at a false discovery rate (FDR) of 0.3 showed that AKT, IGFBP2, LKB1, S6 and Stathmin were predictors of recurrence-free survival (RFS). The cross-validation model was reproducible. The RS model calculated based on the multivariable analysis was -1.1086 x AKT + 0.2501 x IGFBP2 - 0.6745 x LKB1+1.0692 x S6 + 1.4086 x stathmin with a corresponding area under the curve, AUC = 0.856. The RS was an independent predictor of RFS (HR = 3.28, 95%CI = 2.07-5.20, P < 0.001). We found a five-protein model that independently predicted RFS risk in patients with residual TNBC disease. The PI3 K pathway may represent potential therapeutic targets in this resistant disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据